Biocon gets DCGI nod for device to treat critical COVID-19 patients
Posted by
www.biotecnika.org
The company has been granted licence for emergency use of CytoSorb, an
extracorporeal blood purification device CytoSorb to reduce
pro-inflammatory cytokines levels, to treat COVID-19 patients who are
18 years of age or older.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-gets-dcgi-nod-for-device-to-treat-critical-covid-19-patients/articleshow/76027504.cms
Subscribe to:
Post Comments (Atom)
Post a Comment